导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.26% | 4101/4773 |
| 近一周 | -1.88% | 823/5462 |
| 近一月 | -0.73% | 818/5421 |
| 近一季 | -8.56% | 2853/5209 |
| 近半年 | -18.09% | 4241/4920 |
| 近一年 | -3.03% | 3041/4366 |
| 近两年 | 40.95% | 1848/2954 |
| 近三年 | 12.04% | 1696/2253 |
| 成立以来 | 37.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.33% 3594/4961 |
-1.91% 3377/5312 |
- - |
- - |
| 2025 | 29.92% 1361/4813 |
-1.63% 2714/3635 |
11.24% 201/4076 |
7.20% 3468/4524 |
10.74% 180/4813 |
| 2024 | 8.38% 1560/3463 |
-5.78% 1949/2808 |
-2.16% 1144/3014 |
12.46% 2341/3129 |
4.56% 696/3463 |
| 2023 | -10.21% 1275/2656 |
1.26% 1609/2280 |
2.96% 115/2385 |
-10.25% 1975/2515 |
-4.03% 848/2655 |
| 2022 | -25.31% 1308/2207 |
-21.71% 1648/1919 |
3.71% 1106/2016 |
-7.48% 129/2113 |
-0.57% 1625/2208 |
| 2021 | 13.53% 354/1822 |
-17.38% 1198/1255 |
9.96% 508/1330 |
7.00% 200/1466 |
16.79% 48/1822 |
| 2020 | 63.40% 105/1250 |
-1.23% 210/1028 |
10.92% 752/1067 |
27.26% 23/1164 |
17.19% 134/1184 |
| 2019 | 23.34% 630/1092 |
29.95% 265/739 |
-9.00% 626/788 |
5.16% 161/850 |
-0.83% 890/918 |
| 2018 | -25.19% 341/834 |
- - |
-16.82% 567/631 |
2.79% 99/660 |
-12.39% 441/682 |
| 2017 | -14.40% 558/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 广发中证军工ETF联接A VS. 长安沪深300非周期A(740101) |